RxDoctor Payments Data

Erica Costello, PA

Medical · Casper, WYNPI 1760989859

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $141, 7.9 times the $18 reported in 2022.

$246in general payments, 2019–2025

Across 13 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$44
  • Lilly USA, LLC$39
  • AstraZeneca$35
  • Axsome Therapeutics, Inc.$21
  • Otsuka America Pharmaceutical, Inc.$20
  • AbbVie$20
  • plus $67 from 4 others

What the payments were for

  • Food & beverage$246100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$246 in reported general payments places this provider in the 55th percentile of 56 medical providers in Wyoming.

See all medical providers in Wyoming

Medicare billing

Part B allowed, 2024
$88,149
Medicare patients
258
Services billed
1,227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole29$16,720
EliquisApixaban25$8,592
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen135$4,909
Novolog FlexpenInsulin Aspart13$4,548
BreynaBudesonide/Formoterol Fumarate13$3,320
Oxycodone Hcl77$2,060
Pantoprazole Sodium55$1,876
Potassium Chloride16$1,862
Lorazepam71$1,638
Doxycycline Hyclate45$1,574
Gabapentin58$1,423
Olanzapine22$1,174
Tramadol Hcl31$888
Morphine Sulfate ErMorphine Sulfate29$731
Risperidone23$729

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$20$16,72029 claims
Lilly USA, LLCOlanzapine$39$1,17422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 56 medical providers in Wyoming.

Other medical in Casper

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →